Research grants were made to Amsterdam University Medical Center, Duke University, Icahn School of Medicine at Mount Sinai, Johns Hopkins University School of Medicine, Khon Kaen University Thailand, Massachusetts General Hospital Cancer Center/ Harvard Medical School (2), National Institutes of Health, Regents of the University of Minnesota, University of Michigan, and UPMC Montefiore
The Cholangiocarcinoma Foundation, a nonprofit organization funding novel research for bile duct cancer, has awarded the seventh cycle of funding for its Research Fellowship Program. Eleven early-career investigators from 10 institutions were each awarded $50,000 for a one-year study.
Since 2015, the Foundation has awarded 39 research fellowships totaling $2,050,000 in seed funding to early-career investigators to raise awareness about cholangiocarcinoma and inspire innovative, high-quality research. In accordance with the Foundation's research philosophy, the organization supports promising projects that are less likely to get traditional funding.
"Through the Foundation's Research Fellowship Program we hope to gain insights and achieve significant scientific milestones," said Stacie Lindsey, Foundation CEO and founder. "We are proud to honor and support these remarkable young scientists as they carry on the legacies of those for whom the grants are named."
A total of 47 letters of intent were received this year from academic, medical or research institutions in 12 countries (Australia, Canada, France, Germany, Italy, Korea, Netherlands, Spain, Thailand, Turkey, United Kingdom, and the United States). Post-doctoral fellows, instructors with an MD, PhD, Phar.D. or DVM, and junior faculty within the ﬁrst four years of appointment at the time of application were eligible to apply.
The grant review committee is composed of experienced clinicians and scientists from the cholangiocarcinoma field and seasoned research advocates who reviewed the proposals and selected the awardees.
"We are thrilled to announce the 11 Research Fellowship Grants being funded in 2022 by CCF," said Katie Kelley, MD, UCSF Medical Center and Chair of the grants review committee. "These grants will launch a broad range of cutting-edge research projects spanning the basic to clinical research continuum. We believe these projects and the young investigators leading them will produce important breakthroughs for the cholangiocarcinoma community."
- Kathleen and Paul Sidenblad Research Fellowship
Supported by Kathleen and Paul Sidenblad
Daniel Zabransky, Johns Hopkins School of Medicine
D-2-HG as a modulator of fibroblasts and antitumor immunity in the IDH1-mutant cholangiocarcinoma tumor microenvironment
"We are thrilled to announce the 11 Research Fellowship Grants being funded in 2022 by CCF, these grants will launch a broad range of cutting-edge research projects spanning the basic to clinical research continuum. We believe these projects and the young investigators leading them will produce important breakthroughs for the cholangiocarcinoma community."
-Katie Kelley, MD,
UCSF Medical Center
& Chair of the grants review committee.